India’s $42 billion pharmaceutical industry supplies 40% of generic drugs in the US and two-thirds of global HIV medications. However, the rapid expansion has exposed gaps in regulatory oversight. Underfunded labs and inconsistent enforcement have allowed substandard and counterfeit drugs to enter the market, endangering patient safety.